This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kopjar, N. Articles by Gamulin, M. Search for Related Content PubMed PubMed Citation Articles by Kopjar, N. Articles by Gamulin, M. Pubmed/NCBI databases Medline Plus Health Information Breast Cancer Social Bookmarking                         What's this?

Cytogenetic outcomes of adjuvant chemotherapy in non-target cells of breast cancer patients

Institute for Medical Research and Occupational Health, Zagreb, Croatia, nkopjar{at}imi.hr

Ivan Milas

The University Hospital for Tumors, Zagreb, Croatia

Verica Garaj-Vrhovac

Institute for Medical Research and Occupational Health, Zagreb, Croatia

Marija Gamulin

University Hospital Center Rebro, Zagreb, Croatia

Spontaneous and chemotherapy-induced sister chromatid exchanges (SCES) and lymphocyte proliferation rate index (PRI) in cultured peripheral lymphocytes were evaluated in 30 patients with diagnosed breast cancer before and after adjuvant chemotherapy and in 30 healthy women with no known familial history of breast cancer. Before chemotherapy, the breast cancer patients had a significantly increased background level of SCE, and lowered PRI as compared with the healthy women. Marked inter-individual variations were observed in both endpoints among the patients. Significantly elevated frequency of SCE and depressed PRI were recorded in blood samples collected after the first cycle of chemotherapy, with high inter-individual variations in the responses to the chemotherapy. FAC (5-fluorouracil, adriamycin and cyclophosphamide) protocol was the most genotoxic of the protocols studied, but also AC (adriamycin, cyclophosphamide) and CMF (cyclophosphamide, methotrexate and 5-fluorouracil) clearly increased SCE. All protocols significantly retarded lymphocyte proliferation in vitro. Our findings indicate that both SCE and PRI may serve as sensitive biomarkers for the routine detection of critical lesions produced by the administration of antineoplastic drugs in the clinical setting, as well as for possible screening of high-risk individuals among patients who have successfully completed chemotherapy. Human & Experimental Toxicology (2007) 26, 391—399

Key Words: breast cancer • chemotherapy protocols • inter-individual differences • lymphocyte • mitotic activity • sister chromatid exchanges

Human & Experimental Toxicology, Vol. 26, No. 5, 391-399 (2007)
DOI: 10.1177/0960327106076812


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?